Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Especialista en síntesis química para descubrimiento de medicamentos de molécula pequeña

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20160222002
Publicado:
11/04/2016
Caducidad:
11/04/2017
Resumen:
Una pyme británica con experiencia en I+D ha desarrollado un método sintético avanzado para descubrimiento de medicamentos de molécula pequeña. La empresa produce elementos básicos químicos, compuestos heterocíclicos de nitrógeno y moléculas quirales pequeñas para ayudar a compañías farmacéuticas y biotecnológicas en el descubrimiento y desarrollo de medicamentos. El nuevo proceso químico permite la producción muy eficiente de nuevos productos químicos, que se emplean para desarrollar medicamentos en una amplia variedad de áreas de tratamiento, desde la demencia hasta el cáncer. La empresa busca socios potenciales con el fin de establecer acuerdos de fabricación y comercialización con asistencia técnica.

Details

Tittle:
Specialist in chemical synthesis for small molecule drug discovery
Summary:
A North West UK based SME with focus in R-Y-D has developed a state-of-the-art synthetic method for small molecule drug discovery. The company produce chemical building blocks, nitrogen heterocycles and chiral small molecules for the pharmaceutical or biotech organisations to support drug discovery and development. The company is looking to engage with potential partners through commercial agreement with technical assistance and manufacturing agreements.
Description:
This UK university spin-out SME was established in 2014 to produce and supply chiral piperidines and other rich nitrogen heterocycles which are of great importance in drug discovery and development.

The founding team consists of chemists with academic and industrial experience that have developed state-of-the-art synthetic methods in asymmetric hydrogenation / transfer hydrogenation and palladium chemistry.

The patented technology provides access to novel nitrogen heterocyclic chemical building blocks that are used to build new drug molecules. The existing technologies to produce such chemicals are very expensive and time consuming. The new chemical process allows highly efficient production of novel, specialist chemicals that can be used to make new drugs, in a wide range of treatment areas, from dementia to cancer.

Their products can be used as molecular cores, monomer units, linker units or solubilizing groups. Their products have also been used to design a central nervous system (CNS) focused fragment library.

The company is looking to engage with potential partners, predominately with the biotech and pharmaceutical companies via commercial agreements with technical assistance and manufacturing agreement. This company is able to provide off the shelf and bespoke chemicals depending on the stage of drug development.
Advantages and Innovations:
Traditionally when new drugs such as Thalidomide were introduced to treat morning sickness in pregnant women, the lack of chiral purity led to side effects. The specialist products produced by this company are formed with unmatched chiral selectivity, thus avoiding potentially distressing side effects when used to produce new drug molecules.

By using incumbent technologies, there are almost 10 stages required to achieve the purity needed for the research and development work. But this company´s novel manufacturing process will create the exceptionally pure chemicals in just 3 steps. With their patented manufacturing process it is much quicker to produce specialist novel chemicals which can be used in the research work of pharmaceuticals and biotech companies to discover and produce new drugs. Also, potential partners would be able to reduce their R-Y-D cost.
Stage of Development:
Already on the market
IPs:
Secret Know-how,Patents granted

Partner sought

Type and Role of Partner Sought:
Type- SMEs and MNEs operating in pharmaceutical and biotech sector, research institutes and universities.

Role- The company is looking to work with pharmaceutical and biotech companies mainly via commercial agreements with technical assistance or manufacturing agreement. The role of the potential partners would be to use the novel chemicals which can act as building blocks, fragment or screening compounds in their drug discovery process. The company also offers their technical assistance to customise the chiral properties as per the needs of partners to achieve the desired results.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Chinese
English

Keywords

Technology Keywords:
03004007 Pharmaceutics
03004010 Special chemicals, intermediates